Johan E Wallin , Lena E Friberg , Mats O Karlsson Model Based Neutrophil Guided Dose Adaptation in Chemotherapy
|
Lorea Bueno1, Dinesh P de Alwis2, Colin Miles2, Sophie Glatt2, and Iñaki F. Trocóniz1 Semi-Mechanistic Modelling of the Tumour Growth Inhibitory Effects of a New Anti-angiogenic Drug.
|
Celine Pitou, PharmD1; Inaki Troconiz, PhD2; Sophie Glatt, PhD3 Modelling of PK/Efficacy/Toxicity in rats to help design a First Human Dose for a cell cycle inhibitor X
|
Alexandre SOSTELLY (1, 2), Emilie HÉNIN (1), Benoit YOU (2), Pascal GIRARD (2), Mats O KARLSSON (1) Simultaneous modelling of PSA production in Prostatic Benign Hyperplasia (PBH) and prostatic adenocarcinoma patients treated by prostate surgery
|
Emma K. Hansson(1), Brett Houk(2), Michael Amantea(2), Peter Milligan(2), Mats O. Karlsson(1), Lena E. Friberg(1) Pharmacokinetic-Pharmacodynamic Modeling of the Angiogenic Factors VEGF, sVEGFR-2, sVEGFR-3 and sKIT following Sunitinib Treatment in GIST
|
Laurent Nguyen, Aurelie Petain and Christian Puozzo Validation of a neutropenia PK/PD model built from intravenous vinflunine and its application to design phase I trials with oral vinflunine
|
Ludivine Fronton(1), Benoit You(1,2), Marie Pollet-Villard(3), Gilles Freyer(1,2), Michel Tod(1), Olivier Colomban(1), Francois Golfier(3), Pascal Girard(1) Population model of Human Chorionic Gonadotropin to predict resistance in low risk gestational trophoblastic neoplasia patients
|
M. Fontanilles(1), F. Pilleul(2), O. Colomban(1), B. Tranchand(1,5), A.M. Schott(3), J.A. Chayvialle(4), M. Tod(1) Modelization of bevacizumab effect on tumour perfusion assessed by Dynamic Contrast Enhanced Ultrasonography
|
Angelica L. Quartino (1), Lena E. Friberg (1), Sharon D. Baker (2) and Mats O. Karlsson (1) A semi-mechanistic myelosuppression model of docetaxel treatment in liver impaired patients
|
M.N. Trame (1), I.H. Bartelink (2), J. Boos (3), J.J. Boelens (2), G. Hempel (1,3) Population Pharmacokinetics of Dimethylacetamide in Children During Once-daily and Standard IV Busulfan Administration
|
Andreas Lindauer (1), Friederike Kanefendt (1), Cathleen Krambeer (1), Paola di Gion (2), Martina Kinzig (3), Fritz Sörgel (3), Uwe Fuhr (2), Ulrich Jaehde (1) Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib in Healthy Volunteers
|
G. Kersting (1,2), S. Willmann (3), G. Würthwein (2), J. Lippert (3) , J. Boos (2), G. Hempel (1,2) Physiologically-Based Pharmacokinetic (PBPK) Model for High- and Low Dose Etoposide: From Adults to Children
|
M.Guery (1), G.Herbin (1), C.Pobel (1), E.Kiep (1), C.Donamaria (2) Data mining analysis of survival data in cancer of pancreas : first exploratory step for identification and validation of explicative variables
|
Wang, X (1), Anak O (1), Saro J (1), Cramer J (1), Shi M (1), Zhou W (1), Angevin E (2), Escudier B (2), Schran H (1) Population PK modeling and simulation to select a dosing schedule in Phase II trials for a novel TKI agent with time-dependent and nonlinear PK
|
ÅM Johansson (1), N Mayne (2), S Hennig (1), M Perisoglou (2), J Whelan (2), MO Karlsson (1) , JF Standing (1) Pharmacokinetics of high-dose methotrexate in adults and children
|
Damien Cronier (2), Lawrence Gelbert(1), Graham Wishart (2), Alfonso De Dios (1) A fully integrated PK/IVTI/IVE model in mouse to help design the FHD trial for a cell cycle inhibitor X
|
C.Pobel(1), M.Guery(1), G.Herbin(1), E.Kiep(1), C.Donamaria(2) Time to event models of survival in cancer of pancreas : confirmation of explanatory variables pre-selected by bootstrap analysis.
|
Daniel Moreno1, Sara Zalba1, Iñigo Navarro2, Conchita Tros1, Iñaki F. Trocóniz1, María J Garrido1 Pharmacokinetics and antitumor efficacy characterization of cisplatin-loaded PLGA nanoparticles in tumor-bearing mice.
|